Clinical Decision Support Tools Can Help Doctors Quickly and Accurately Diagnose Ebola and Other Infectious Diseases
October 03, 2014 06:30 ET
|
Logical Images
ROCHESTER, N.Y., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Four years ago, the Institute of Medicine recommended the Department of Health and Human Services promote the use of clinical decision support tools...
Dallas Ebola Patient Raises Serious Concerns About U.S. Preparedness, States Association of American Physicians and Surgeons (AAPS)
October 01, 2014 13:18 ET
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Oct. 1, 2014 (GLOBE NEWSWIRE) -- As CDC director Thomas Frieden said at one point, it was inevitable that Ebola would reach the U.S. Now that it has, the CDC expresses confidence that...
Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
September 29, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...
Calls for Physician Activism on 'Climate Change' Misdirected, States Association of American Physicians and Surgeons (AAPS)
September 24, 2014 11:19 ET
|
Association of American Physicians and Surgeons
TUCSON, Ariz., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Americans and other peoples of the world are facing grave threats to their health and well-being, states the Association of American Physicians and...
Ebola-stricken Community in Liberia Receives Safe Water through Charleston based Non-Profit, Water Missions International
September 22, 2014 20:09 ET
|
Water Missions International
CHARLESTON, S.C., Sept. 22, 2014 (GLOBE NEWSWIRE) -- As the international response to the Ebola outbreak in West Africa continues to ramp up, Water Missions International (WMI), a non-profit Christian...
Hemispherx Biopharma and the Swiss Department of Defense, Civil Protection and Sports Expand Their Collaborative Research Agreement to Include the Study of Alferon(R) and Ampligen(R) Against the Ebola Virus
September 10, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it expanded its Collaborative Research Agreement to test...
Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Agree to Collaborate in Studying Alferon(R) and Ampligen(R) Against the Ebola Virus
September 08, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that the Company and USAMRIID scientists have agreed to test...
PositiveID's Handheld Bio-Threat Testing Device Featured in Computerworld
August 22, 2014 08:30 ET
|
PositiveID Corporation
PositiveID's Firefly prototype device could be used to detect viruses such as Ebola and other bio-threats
DELRAY BEACH, Fla., Aug. 22, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID"...
PositiveID's Firefly Dx System Featured on Fox News San Francisco
August 07, 2014 10:41 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., Aug. 7, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced...
Hemispherx's Two Drugs, Ampligen(R) and Alferon(R) Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
August 04, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a peer-reviewed electronic publication entitled "Sensitivity of SARS/MERS CoV to Interferons and...